

epitomee

shaping your health

Ingestible Therapeutic Platform

Treating Chronic Disease through the GI Tract

September 2023



This presentation (the “**Presentation**”) is for informational purposes only and does not constitute or form any part of any offer or solicitation to buy or subscribe for securities of Epitomee Medical Ltd. (the “**Company**”) and should not be regarded as a recommendation or an opinion on such matters. The information included in this Presentation is not comprehensive and does not include all the information with respect to the Company and its business required for any decision concerning an investment in the Company’s securities. This Presentation includes forecasts, estimates, assessments, expectations and other information, intent or belief pertaining to future events and/or matters, which constitute “forward-looking statements” as defined in the Securities Law 5728-1968, which is based on current expectations, projections and assumptions about future events. Actual results may differ materially due to variety of factors, some of which the Company has no control over and cannot be reasonably foreseen at this date, including, but not limited to: dependency on third parties engaged by or who contracts the Company and its services, change in the overall economy; the duration and severity of the COVID-19 (coronavirus) pandemic and its impact on the Company and on local and global economy and the Company’s ability to manage and develop its business. Such information may not materialize, in whole or in part, or may materialize in a manner significantly different to that forecast. Therefore, actual future results, performances or achievements of the Company may differ materially from what is or may be expressed or implied in this Presentation. Certain information and factual statements (including markets or trends) contained herein are based on or derived from publicly available documents or independent third-party sources the accuracy of such information and the assumptions on which such information is based have not been independently verified. The past performance information contained herein is not indicative of future results and there can be no assurance that the Company will achieve comparable results or that the Company will be able to implement its investment strategy or achieve any investment objective.

Management Team



Shimon Eckhouse, PhD
Co-founder and Chairman

Founder of Syneron Nasdaq: ELOS & Lumenis
Nasdaq: LMNS, Sofwave Medical TLV: SOFW and others



Dan Hashimshony, PhD
Chief Executive Officer

Founder & CEO-Dune Medical Devices
Chief Scientist X-technologies, and others



Gal Aharonowitz
COO

SHL, VP R&D Lumenis,
GM Israel
Dune medical



Yael Kenen, PhD
VP Clinical Affairs

TEVA, Global Clinical Drug
Development Director



Gil Cohen, PhD
VP R&D

SCO Dune Medical Devices,
Hebrew University of Jerusalem



Maya Gabrieli, CPA
VP Finance

Plastopil Hazorea LTD,
KPMG



Safi Landskroner
VP Business Development

Dexcel Pharma, Mapi Pharma,
Chartwell Pharmaceuticals



Dr. Ruthie Amir, MD.
Chief Medical & Regulatory Officer

Global VP Regulatory
Syneron, Sofwave Medical

Company Highlights



Breakthrough Tech

Ingestible, Shapeshifting Platform

- Creates self-ingested, swallowable devices that act along the GI tract
- Achieves therapeutic outcomes in prevalent diseases



Market Potential

Multi Billion \$ Market

- Weight management > **\$200B** (Commercialization stage)
- Biologics delivery > **300B** (Growth engine)



Strategic Alliances

With Global Conglomerates

- **Weight management:** Global commercialization and marketing with **Nestle**
- **Biologics:** Advancing collaborations with big pharma on biologic oral delivery



Global Commercialization

Regulatory Progress

- Cleared in: Europe, Israel
- Completed pivotal study for FDA 510(k) showing great clinical outcomes
- Targeting FDA clearance & market launch in 2024



Protected Innovation

Intellectual Property

- 30 granted patents
- 12 pending patents



Strong Cash Position

IPO TASE Dec 2021

- Current cash balance ~ \$38M

A Platform Technology with Various Applications

Adaptable in function, duration and location of operation



ORAL ADMINISTRATION

Easy ingestion with no clinical procedures



TARGETED DEPLOYMENT

Precise delivery to specific therapeutic location



TRANSIENT ACTIVITY

Temporary engagement and complete clearance



SAFE

Designed with patient safety at the forefront

1

Weight Management:
active in the stomach

2

Oral Biologics: drug carrier for
delivery in the small intestine

Strategic Focus

Weight Management

Market Potential:

\$200B



Our Solution:

Drug-free, Ingestible Treatment

- Imitates solid food intake
- Daily therapy

Biologics Delivery

Market Potential:

\$300B



Our Solution:


Protected, Oral Delivery

- Eliminates the need for injections
- Improves bioavailability

epitomee

shaping your health

Weight Management Solution Overview



2.6B People Worldwide are Overweight or Obese




Weight Management Capsule



Creating a sense of fullness:

The capsule expands in the stomach into a semi-rigid triangle, imitating solid food through its interaction with the stomach wall.



Weight Management Capsule – Mechanism of Action

Activating the body's natural mechanisms to regulate food intake



01

Ingesting


Capsule reaches the stomach



02

Shapeshifting


Expands into a semi-rigid triangular shape in response to the stomach's pH



03

Resisting

Interacts with stomach's mechanical sensors, inducing early satiety



04

Clearing out

After several hours, the device dissolves within minutes and naturally exits the body



Surging Market Demand Driven by the Rise of GLP-1 Injection



Rising Demand for 'Easy Fix' Solutions

The market is increasingly seeking effective, convenient treatments.

Willingness to Pay

Users are demonstrating a readiness to pay out of pocket for solutions that work.


Challenges with Current Treatments

High costs, side effects and the injection delivery method result in significant user attrition.

Opportunity for Alternative Solutions

GLP-1 dropouts are primed candidates looking for more sustainable & user-friendly treatment. Maintenance treatment with Epitomee- avoiding weight gain.

GLP1 Market Growth



Epitomee: An Alternative for a Wider Audience



Epitomee's technology offers a sustainable, effective weight loss & weight management solution for individuals with a BMI >25 (with or without co-morbidities), targeting weight loss between 5kg to 15kg.



Epitomee Weight Management Capsule – Key Attributes



DRUG-FREE

Safe weight management with minimal side effects



INGESTIBLE CAPSULE

Easy to use

2
DAILY

TAKEN TWICE DAILY

Aligns with common daily medication protocols



IMITATES SOLID FOOD

Triggers a sensation of satiety



HIGH SAFETY PROFILE

High safety profile - ideal for prolonged use



Epitomee 'RESET' Clinical Trial Design

Randomized Evaluation of Efficacy and Safety of the Epitomee Capsule Trial

The effect of the Epitomee Capsule on Body Weight in Patients with Overweight and Obesity, with/without Prediabetes



Study Design

Double-blind, Placebo Controlled,
Randomized, Multicenter, Adaptive
Design Study

Main Patient Inclusion Criteria

1. Adults, BMI 27-40 kg/m²
2. Normoglycemic & Prediabetic subjects

Sample Size

279 participants

Comprehensive Analysis



Multi-Parametric Assessment

The pivotal trial encompasses a broad array of health metrics, examined throughout the trial: Chemistry (Serum Insulin, HOMA-IR, FPG & HBA1C, Triglycerides), Hematology, Coagulation (PT/INR), Urine Analysis



Subcategories of Interest

Detailed analysis enables identifying specific benefits within patient subgroups.

Epitomee Digital Add on Study Platform (by Setpoint health)




Weight Scale



Physical Activity Tracker



Study Portal Access to patients and sites teams



Study App Access



Study App Dashboard



WEIGHT
MEASUREMENTS



PERSONAL
GOALS



PHYSICAL
ACTIVITY
TRACKING



REMOTE
MONITORING




CONTINUES
COMMUNICATION
WITH CLINIC



CAPSULE INTAKE



FOOD DIARY



Primary Endpoint Criteria Achieved



Co-primary Efficacy Endpoints & Success Criteria

1 Mean change in body weight (%) is greater, clinically & statistically, in Epitomee arm Vs control arm

Epitomee treatment > **Control treatment**

Significantly greater

2 Proportion of subjects who lost at least 5% of their baseline weight is greater than the threshold (35%)

Epitomee treatment > **35% threshold**

Strong statistical significance

Primary Safety Endpoint

3 Incidence of device-related serious treatment emergent adverse events (SAEs) from the randomization up to 24 weeks post-randomization

Zero Related SAEs

Previous Clinical Trial Results



Efficacy & Safety Demonstrated in Clinical Trials



12 week duration




High Completion Rate




7 out of 10

Completers experienced weight loss



Notable Waistline Reduction



The entire cohort **reduced ~5 cm** of their waist circumference on average

N=78
>10,000
ingested capsules

Clinical Trial Data Reveals Additional Clinical Value



12 week duration



PREDIABETES IMPROVEMENT



Prediabetic participants

experienced significant reduction
in HbA1c and/or glucose levels

CARDIOVASCULAR RISK FACTOR REDUCTION




21 of the 35 participants

with high blood pressure reported

- Systolic BP: Reduced by an average of 13mmHg
- Diastolic BP: Reduced by an average of 10mmHg



Nestlé
HealthScience®
Strategic Partnership



Strategic Partnership: Nestle & Epitomee (Aug 2020)



Exclusive License

Global commercialization rights for Epitomee's weight loss product

Joint Market Development

Expand and optimize market reach and accessibility

Launch Horizon

Market launch planned for 2024



High Level Payment Scheme



Up to 10%

Growing Royalties

\$17M

Paid Development Milestones


**Cost Plus
Markup**

on Product

+\$105M


Additional potential in
Development & Sales Milestones

Advancing Manufacturing



Epitomee Advances Global Registration

Market-specific registration



epitomee

shaping your health

Biologics Delivery Solution Overview



Transforming Biologic Delivery: A Multibillion-Dollar Opportunity

Capitalizing on a \$300 Billion Market Seeking Oral Solutions



The Current Situation

- Biologics are administered via painful injections
 - Low adherence to treatment protocols due to discomfort of the patient
-

The Unmet Need

- Pharma companies are actively seeking oral delivery alternatives to improve patient compliance
-

Epitomee's Solution


- An innovative platform for the oral delivery of biologics
-

Biologics Delivery Capsule



Enabling effective delivery:

Once in the small intestine, the capsule expands into a scaffold that carries a biological payload on its outer shell. The expanding scaffold affixes to the intestinal wall, maximizing payload proximity to achieve optimal absorption.





Biologics Delivery Capsule – Mechanism of Action

Achieving effective bioavailability through direct contact

01

Ingesting

Capsule reaches the small intestine



02

Shapeshifting


Muco-adhesive layer ensures direct contact with intestinal wall for protected absorption of payload



03

Payload Delivery

Once contact is achieved the payload is released in a controlled manner for a predetermined period



04

Clearing out

When planned substance release is completed, the device disintegrates and naturally exits the body





Epitomee: Improving Adherence for Millions



INGESTIBLE

Non-invasive delivery, eliminating the need for injections



A-TRAUMATIC DEPLOYMENT

Gentle interaction with the intestinal wall



PROTECTED ABSORPTION

Direct intestinal contact safeguards biologics from harsh digestive conditions



TRANSIENT OPERATION

Naturally dissolves and clears out after use




EASY-TO-USE


Improved patient compliance, boosting treatment adherence

By achieving direct, a-traumatic contact with the intestinal wall, the delivery device ensures effective bioavailability, offering patients a non-invasive treatment method that enhances adherence.

Development Strategy: Generating Revenue Ahead of Product Commercialization



Transforming Biologic Treatments to Achieve Blockbuster Impact



Thank you

Contact

Dan Hashimshony PhD, CEO

Dan@epitomeemmedical.com

References

- https://www.worldobesityday.org/assets/downloads/World_Obesity_Atlas_2023_Report.pdf
- <https://www.prnewswire.com/news-releases/global-glucagon-like-peptide-1-glp-1-market-report-2023-a-24-1-billion-market-by-2027-from-16-53-billion-in-2021-with-rising-cases-of-diabetes-and-obesity-contributing-to-growth-301733431.html>
- <https://www.globenewswire.com/news-release/2020/12/17/2147220/0/en/Global-Weight-Management-Industry.html>
- <https://www.verifiedmarketresearch.com/product/biologics-market/>
- <https://www.grandviewresearch.com/industry-analysis/glp-1-receptor-agonist-market>
- <https://www.businesswire.com/news/home/20210325005642/en/Global-TNF-Alpha-Inhibitors-Market-Report-2020-2030-COVID-19-Growth-and-Change---Market-is-Expected-to-Decline-from-40.66-Billion-in-2019-to-39.01-Billion-in-2020---ResearchAndMarkets.com>
- Basal Insulin (Long-Acting Insulin) - Market Projections to 2024 with Company Profiles & Share Analysis - ResearchAndMarkets.com | Business Wire
- Human Growth Hormone (HGH) Market | 2021 - 26 | Industry Share, Size, Growth - Mordor Intelligence
- Global Parathyroid Hormone Market Data And Industry Growth Analysis (thebusinessresearchcompany.com)
- Interferon Beta Drugs Market Size, Trends, Shares, Insights, Forecast - Coherent Market Insights
- <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700511/>